

## Amendments to the Claims

### Listing of the Claims:

This Listing of the Claims will replace all prior versions, and listings of the claims in the application.

1-124 (Canceled)

125. (Presently Amended): A pharmaceutical composition comprising a hapten-carrier conjugate, said pharmaceutical composition comprising


at least one hapten which is nicotine or a nicotine derivative; and

[[a]] at least one carrier which is a pseudomonas exotoxin ~~bacterial toxin,~~

and wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	$(CH_2)_nQ$
CJ 1.1	$CO_2Q$
<del>CJ 1.2</del>	<del><math>COQ</math></del>
<del>CJ 1.3</del>	<del><math>CH_3</math></del>
CJ 2	$OCO(CH_2)_nQ$
CJ 2.1	$OCOCH=Q$
CJ 2.2	$OCOCH(O)CH_2$
CJ 2.3	$OCO(CH_2)_nCH(O)CH_2$
CJ 3	$CO(CH_2)_nCOQ$
CJ 3.1	$CO(CH_2)_nCNQ$
CJ 4	$OCO(CH_2)_nCOQ$
CJ 4.1	$OCO(CH_2)_nCNQ$
CJ 5	$CH_2OCO(CH_2)_nCOQ$
CJ 5.1	$CH_2OCO(CH_2)_nCNQ$
CJ 6	$CONH(CH_2)_nQ$
CJ 7	$Y(CH_2)_nQ$
CJ 7.1	$CH_2Y(CH_2)_nQ$
CJ 8	$OCOCH(OH)CH_2Q$
CJ 8.1	$OCO(CH_2)_nCH(OH)CH_2Q$
CJ 9	$OCOC_6H_5$

CJ 10



, wherein Q' is a modified protein; and

CJ 11

$YCO(CH_2)_nCOQ_x$

and wherein for each branch, n is independently an integer; Y is S, O, or NH; and Q is a ~~bacterial toxin carrier or~~ selected from the group consisting of:

- (i) —H;
- (ii) —OH;
- (iii) —CH<sub>2</sub>;
- (iv) —CH;
- (iv a) —OCH<sub>3</sub>;
- (v) —COOH;
- (vi) a halogen;
- (vii) an activated ester or esters, such as 2-nitro-4-sulfophenyl ester and N-oxysuccinimidyl ester;
- (viii) a group or groups reactive toward the carrier, such as a mixed anhydride, acyl halide, acyl azide, alkyl halide, N-maleimide, imino ester, isocyanate, and isothiocyanate;
- (ix) the carrier; and
- (x) another “branch” identified by its “CJ” reference number;

and wherein said hapten-carrier conjugate is capable of eliciting an antibody response against nicotine in a human.

126. (Presently Amended): The ~~hapten-carrier conjugate~~ pharmaceutical composition of claim 125, wherein n is from 3 to 20.

127. (Canceled)

128. (Presently Amended): The ~~hapten-carrier conjugate~~ pharmaceutical composition of claim 125, wherein greater than one hapten is coupled to the carrier.

129. (Canceled)

130. (Canceled)

131. (Presently Amended): ~~A pharmaceutical preparation comprising the hapten-carrier conjugate~~ The pharmaceutical composition of claim 125, ~~and further comprising a~~ pharmaceutically acceptable excipient.

132. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim ~~131~~ 125, further comprising an adjuvant.

133. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim 132, wherein the adjuvant is alum or RIBI adjuvant.

134. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim 133, wherein the adjuvant is alum.

135. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim 134, wherein the alum is aluminum hydroxide or aluminum phosphate.

136. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim ~~131~~ 125, further comprising an auxiliary agent or supplementary active compound.

137. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim ~~131~~ 125 which is suitable for parenteral administration to a human.

138. (Presently Amended): The pharmaceutical ~~preparation~~ composition of claim ~~131~~ 125 which is suitable for oral, dermal or topical administration to a human.

139. (Canceled)

140. (Canceled)

141. (Canceled)

142. (Presently Amended) ~~A pharmaceutical preparation comprising the hapten carrier~~ The pharmaceutical composition of claim 141~~125~~, ~~and further comprising a~~ pharmaceutically acceptable carrier.